Warbington Timothy's Form 4 filing
Creative Medical Technology Holdings, Inc. (CELZ) · filed Sep 25, 2026
- Accession no.
- 0001477932-26-005811
- Filed
- Sep 25, 2026, 6:00 PM ET
- Trade date
- Sep 24, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Warbington TimothyCIK 0001674492 | Director, Officer (President & CEO), 10% Owner |
| Creative Acquisition Corp.CIK 0002106672 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 24, 2026 | Common Stock | AGrant or awardAcquired | +1,000,000 | –F1 | – | 1,034,904 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The shares of common stock were issued to Creative Acquisition Corp. ("CAC") pursuant to a Stock Purchase Agreement dated September 24, 2026 (the "SPA"), between CAC and the Issuer, pursuant to which the Issuer purchased 4,000,000 shares of common stock of BioDefense, Inc. ("BioDefense") from CAC for a purchase price consisting of $200,000 in cash and 1,000,000 shares of the Issuer's common stock. After giving effect to the transactions under the SPA, the Issuer owns 80% (16,000,000) of the outstanding shares of BioDefense and CAC owns 20% (4,000,000) of the outstanding shares of BioDefense. Timothy Warbington is the Chairman and Chief Executive Officer of CAC, indirectly owns all of its outstanding shares of capital stock, and beneficially owns the shares held by CAC.
Referenced by the price of 1 transaction in Table I.